CRL-40,941, known by its alternative names fladrafinil and fluorafinil, falls within the category of eugeroics and shares a close chemical relationship with adrafinil and modafinil. Specifically, it is the bis(p-fluoro) ring-substituted derivative of adrafinil. One noteworthy distinction is that CRL-40,941 has demonstrated anti-aggressive effects in animals, a characteristic not observed with adrafinil, and it is reported to be approximately 3 to 4 times more potent than adrafinil.
CRL-40,941, or fladrafinil and fluorafinil, is a chemical compound categorized as a eugeroic. It shares a close chemical relationship with adrafinil and modafinil.
What is a eugeroic?
A eugeroic is a class of drugs that promotes wakefulness and alertness. They are often used to address sleep-related disorders and enhance cognitive function.
How does CRL-40,941 differ from adrafinil and modafinil?
CRL-40,941 is the bis(p-fluoro) ring-substituted derivative of adrafinil. Notably, it has been found to exhibit anti-aggressive effects in animals, a quality not observed with adrafinil. Additionally, it is purported to be significantly more potent, approximately 3 to 4 times stronger than adrafinil.
What are the potential applications of CRL-40,941?
CRL-40,941 is primarily explored for its potential to promote wakefulness and cognitive enhancement. It may be used for sleep disorders or situations requiring heightened alertness.
Is CRL-40,941 approved for medical use?
As my last knowledge update in September 2021, CRL-40,941 had not received regulatory approval for medical use in many countries. It is crucial to stay informed about its regulatory status, which may change over time.
What are the reported side effects of CRL-40,941?
The side effects of CRL-40,941, particularly with prolonged use, still need to be fully understood. Users should exercise caution and consult healthcare professionals if considering its use.
Where can I find more information about CRL-40,941?
To access in-depth information about CRL-40,941, consider referring to scientific literature, research studies, and reliable sources. It’s essential to stay updated on developments regarding its regulatory status and any potential medical applications.
US 4489095, Lafon L, “Halogenobenzhydrylsulfinylacetohydroxamic acids”, published 1984-12-18, assigned to Laboratoire L. Lafon